Predictive Oncology Announces Appointment of Oncology Translational Research Leader Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory Board
04 avr. 2023 08h30 HE
|
Predictive Oncology Inc.
EAGAN, Minn., April 04, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning...
Predictive Oncology Announces Collaboration with Integra Therapeutics to Advance Gene Therapy
30 mars 2023 08h30 HE
|
Predictive Oncology Inc.
EAGAN, Minn., March 30, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announces it is...
Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update
21 mars 2023 17h15 HE
|
Predictive Oncology Inc.
EAGAN, Minn., March 21, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning...
Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs
17 mars 2023 07h00 HE
|
Predictive Oncology Inc.
EAGAN, Minn., March 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) together with Cancer Research Horizons, the innovation engine at the core of the world’s largest private...
Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common Stock
16 mars 2023 17h15 HE
|
Predictive Oncology Inc.
EAGAN, Minn., March 16, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that its Board of Directors declared a dividend of...
Predictive Oncology Engages LifeSci Advisors as Strategic Investor Relations Partner
14 mars 2023 08h30 HE
|
Predictive Oncology Inc.
EAGAN, Minn., March 14, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities,...
Predictive Oncology Issues Letter to Shareholders
09 mars 2023 08h30 HE
|
Predictive Oncology Inc.
EAGAN, Minn., March 09, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities to...
Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence
23 févr. 2023 08h30 HE
|
Predictive Oncology Inc.
EAGAN, Minn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) and Cvergenx, Inc. today announced an agreement to form a strategic partnership that has the potential to...
Predictive Oncology launches ACE program to partner with academic and research institutions to advance their drug discovery initiatives
21 févr. 2023 08h30 HE
|
Predictive Oncology Inc.
EAGAN, Minn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the launch of ACE (Accelerating Compound Exploration), a program to advance the oncology drug...
Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer
03 févr. 2023 08h31 HE
|
Predictive Oncology Inc.
EAGAN, Minn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will...